Live feed11:59:00·1969dPRReleasevia QuantisnowLigand Partner Travere Therapeutics Announces Achievement of Interim Proteinuria Endpoint in the Ongoing Phase 3 DUPLEX Study of Sparsentan in Focal Segmental GlomerulosclerosisByQuantisnow·Wall Street's wire, on your screen.TVTX· Travere Therapeutics Inc.LGND· Ligand Pharmaceuticals IncorporatedHealth CareOriginal source
